Recurrent Lymphoma Active Not Recruiting Phase 1 Trials for Irinotecan (DB00762)

IndicationStatusPhase
DBCOND0073930 (Recurrent Lymphoma)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03323034Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or LymphomaTreatment